BIOD has quietly developed an improved mixed insulin product compatible with Lantus, which would allow the “holy grail” combination fast-acting/long acting insulin to be created. They are a top pick with an FDA review date of October 30th. Price… More
This is my second underperform pitch on Biodel. For context I will cite previous pitches:From an outperform pitch: The company will certainly have to repeat their phase III trial if they want FDA approval for Viaject (for type I diabetes). If they… More
